C3G Trial places still available

Places are still available on the Factor D Inhibitor Phase 2 C3G Clinical Trial.

Achillion Pharmaceuticals is currently carrying out phase 2 clinical trials of their drug ACH-0144471, a Factor D inhibitor with the aim of treating C3G. Initial results have been positive. Places are available throughout the world including the UK and North America.

UK patients can find out whether they can be part of the trial by contacting Professor Liz Lightstone PhD FRCP at Imperial College London via e-mail at l.lightstone@imperial.ac.uk.

Non UK patients can find trial location information on clinicaltrials.gov. The FDA has approved inclusion of patients aged 12 to 18 in the trial. Achillion can be contacted for more information on 2037525566 or C3GTrialInquiries@achillion.com

For more details including inclusion and exclusion criteria for the trial please follow this link to clinicaltrials.govĀ https://clinicaltrials.gov/show/NCT03369236




Get the latest

For up-to-date news and information visit our news or join our mailing list below:

Join us, it's free!

Upcoming events

View upcoming events and dates in our MPGN/DDD Support Group calendar.

View Calendar


Find out what we’re doing right now and how you can help:

Read more